MedTrace Logo

Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease

NCT05691114 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-17

No results posted yet for this study

Summary

This is a single-center, single-arm, dose escalation study, to explore the safety, tolerability and efficacy of human amniotic epithelial stem cells (hAESCs) for idiopathic Parkinson's disease (PD).

Conditions

  • Idiopathic Parkinson's Disease

Interventions

BIOLOGICAL

hAESCs

human Amniotic Epithelial Stem Cells

Sponsors & Collaborators

  • Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

    collaborator INDUSTRY

  • Shanghai East Hospital

    lead OTHER

Principal Investigators

  • Jingwen Wu, M.D. · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2025-02-28
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05691114 on ClinicalTrials.gov